Epizyme’s (EPZM) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Epizyme (NASDAQ:EPZM) in a report released on Monday morning. They currently have a $21.00 target price on the biopharmaceutical company’s stock. Wedbush also issued estimates for Epizyme’s Q4 2018 earnings at ($0.48) EPS, FY2018 earnings at ($1.93) EPS, Q1 2019 earnings at ($0.49) EPS, Q2 2019 earnings at ($0.51) EPS, Q3 2019 earnings at ($0.47) EPS, Q4 2019 earnings at ($0.48) EPS, FY2019 earnings at ($1.95) EPS, FY2020 earnings at ($1.77) EPS, FY2021 earnings at ($1.07) EPS and FY2022 earnings at $0.42 EPS.

Other equities analysts have also recently issued research reports about the company. Cann reissued a buy rating and set a $27.00 price target on shares of Epizyme in a report on Thursday, August 2nd. Cowen reissued a buy rating on shares of Epizyme in a report on Monday, September 24th. BidaskClub raised Epizyme from a sell rating to a hold rating in a report on Thursday, August 16th. ValuEngine raised Epizyme from a sell rating to a hold rating in a report on Thursday, July 26th. Finally, Morgan Stanley set a $12.00 price target on Epizyme and gave the stock a hold rating in a report on Friday, September 7th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. Epizyme has a consensus rating of Hold and a consensus price target of $20.50.

NASDAQ EPZM traded down $0.09 during midday trading on Monday, hitting $7.83. The company had a trading volume of 6,056 shares, compared to its average volume of 689,021. The stock has a market capitalization of $603.26 million, a PE ratio of -3.60 and a beta of 1.89. Epizyme has a twelve month low of $7.41 and a twelve month high of $21.40.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings data on Friday, November 2nd. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.07. As a group, equities research analysts expect that Epizyme will post -1.97 earnings per share for the current fiscal year.

In other news, Director David M. Mott acquired 416,667 shares of Epizyme stock in a transaction that occurred on Friday, October 5th. The shares were acquired at an average price of $9.00 per share, for a total transaction of $3,750,003.00. Following the transaction, the director now directly owns 12,088 shares of the company’s stock, valued at approximately $108,792. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 21.50% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. bought a new stake in Epizyme during the 1st quarter worth $187,000. Jane Street Group LLC bought a new stake in shares of Epizyme in the 1st quarter valued at about $273,000. BB&T Securities LLC grew its position in shares of Epizyme by 45.5% in the 2nd quarter. BB&T Securities LLC now owns 16,000 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 5,000 shares during the last quarter. BlueMountain Capital Management LLC bought a new stake in shares of Epizyme in the 2nd quarter valued at about $320,000. Finally, Trexquant Investment LP bought a new stake in shares of Epizyme in the 2nd quarter valued at about $328,000. Institutional investors and hedge funds own 74.09% of the company’s stock.

Epizyme Company Profile

Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.

Featured Article: Bond

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply